Additionally, although strong evidence from experimental models and human data in vivo and in situ suggested potential of anti-IL17 blockade as a therapeutic target in RA (71, 72), psoriasis (73), and spondyloarthritis (74), strong efficacy for RA and other similar diseases has not shown in comparison to placebo (75). This evidence concerns the gene IL17A and rheumatoid arthritis.